Crysvita Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Crysvita market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historic period can be attributed to increased focus on early diagnosis and intervention of genetic disorders, advancements in genetic research enabling precise identification of XLH, and supportive healthcare initiatives promoting access to innovative treatments.

Market growth during the forecast period can be attributed to increasing efforts by patient advocacy groups to promote education and understanding, advancements in genetic research enabling earlier and more accurate diagnosis, and greater focus on improving access to innovative treatments. Expanding healthcare initiatives targeting rare genetic disorders will also contribute to growth. Major trends in the forecast period include the management of XLH and TIO, with ongoing research and clinical experience contributing to its evolving therapeutic profile.

The increasing number of clinical trials is expected to propel the growth of the crysvita market. Clinical trials are essential for advancing treatments for conditions like Acute Spinal Cord Injury (SCI) and are driven by the demand for new therapies, medical advancements, personalized treatments, and growing healthcare needs. Crysvita plays a critical role in clinical trials by providing targeted treatment for X-linked hypophosphatemia (XLH), allowing the evaluation of its safety and efficacy in diverse patient populations. According to the United States National Library of Medicine, the number of registered clinical trials increased from 477,227 in 2023 to 506,371 in 2024 across 221 countries, indicating significant growth in clinical research. The increasing number of clinical trials is thereby driving the growth of the crysvita market.

Rising personalized medicine is another factor expected to propel the growth of the crysvita market. Personalized medicine tailors treatments based on individual characteristics like genetics, environment, and lifestyle, leading to more effective and precise outcomes. Crysvita exemplifies personalized medicine by offering targeted treatment for X-linked hypophosphatemia (XLH), addressing the specific genetic and metabolic needs of patients to improve their bone health and overall quality of life. In 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022, including treatments for cancer and other conditions, according to the Personalized Medicine Coalition. This rise in personalized medicine is contributing to the growth of the crysvita market.

In August 2022, OMERS Capital Markets, a Canada-based investment company, acquired a portion of North American royalties on Crysvita from Ultragenyx Pharmaceutical Inc. for $500 million. This acquisition underscores the growth potential of Crysvita in the rare disease market and reflects the increasing investor interest in the treatment's ability to impact patient outcomes. Ultragenyx Pharmaceutical Inc. is the U.S.-based biopharmaceutical company responsible for manufacturing Crysvita (burosumab).

Major players operating in the crysvita market are Kyowa Kirin Co. Ltd., and Ultragenyx Pharmaceutical Inc.

North America was the largest region in the crysvita market in 2024. The regions covered in crysvita report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the crysvita market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Crysvita is a prescription medication used to treat X-linked hypophosphatemia (XLH), a rare genetic disorder that results in low phosphate levels in the blood, leading to weak bones, bone pain, and other skeletal issues.

The key formulations of crysvita are 10 mg, 20 mg, and 30 mg. Crysvita 10 mg typically contains cysteine as its active ingredient, often in the form of a cysteine-based supplement. The medication is used for various patient demographics, including pediatric and adult populations. It is indicated for the treatment of conditions such as X-linked hypophosphatemia and tumor-induced osteomalacia. Crysvita is administered in settings like hospitals, clinics, and others.

The crysvita market research report is one of a series of new reports that provides crysvita market statistics, including crysvita industry global market size, regional shares, competitors with a crysvita market share, detailed crysvita market segments, market trends, and opportunities, and any further data you may need to thrive in the crysvita industry. This crysvita market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The crysvita market consists of sales of injection and drug formulation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.